DK1388008T3 - Fremgangsmåder til identifikation af antivirale forbindelser - Google Patents

Fremgangsmåder til identifikation af antivirale forbindelser

Info

Publication number
DK1388008T3
DK1388008T3 DK02733606T DK02733606T DK1388008T3 DK 1388008 T3 DK1388008 T3 DK 1388008T3 DK 02733606 T DK02733606 T DK 02733606T DK 02733606 T DK02733606 T DK 02733606T DK 1388008 T3 DK1388008 T3 DK 1388008T3
Authority
DK
Denmark
Prior art keywords
cells
viruses
life cycle
virus
methods
Prior art date
Application number
DK02733606T
Other languages
Danish (da)
English (en)
Inventor
Govert Johan Schouten
Ronald Hendrik Peter Brus
Alphonsus Gerardus C Uytdehaag
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1388008T3 publication Critical patent/DK1388008T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/075Adenoviridae
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK02733606T 2001-05-07 2002-05-06 Fremgangsmåder til identifikation af antivirale forbindelser DK1388008T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28954101P 2001-05-07 2001-05-07
EP01201657A EP1256803A1 (de) 2001-05-07 2001-05-07 Verfahren zur Identifizierung von antiviralen Verbindungen
PCT/NL2002/000296 WO2002090982A1 (en) 2001-05-07 2002-05-06 Methods for the identification of antiviral compounds

Publications (1)

Publication Number Publication Date
DK1388008T3 true DK1388008T3 (da) 2009-02-09

Family

ID=8180262

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02733606T DK1388008T3 (da) 2001-05-07 2002-05-06 Fremgangsmåder til identifikation af antivirale forbindelser

Country Status (8)

Country Link
US (1) US7163787B2 (de)
EP (2) EP1256803A1 (de)
AT (1) ATE410679T1 (de)
AU (1) AU2002306089B2 (de)
CA (1) CA2445911C (de)
DK (1) DK1388008T3 (de)
NZ (1) NZ529094A (de)
WO (1) WO2002090982A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7297680B2 (en) * 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
EP2069483A4 (de) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co Rekombinante rhinovirus-vektoren
EP2257308A4 (de) * 2008-03-27 2012-06-27 Sanofi Pasteur Biologics Co Rekombinante rhinovirus-vektoren
SI2454364T1 (sl) * 2009-07-16 2014-08-29 Crucell Holland B.V. Izdelava polio virusa v visokih titrih za izdelavo cepiva

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527814B1 (de) * 1990-04-03 1994-12-28 Southwest Foundation For Biomedical Research Immortalisierte primate hepatozyte zellinie
US6200745B1 (en) * 1993-09-09 2001-03-13 The Penn State Research Foundation Vitro assay system using a human cell line for testing the effectiveness of anti-papilloma viral agents
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US5939253A (en) * 1996-04-26 1999-08-17 Diagnostic Hybrids, Inc. Compositions and methods for detecting viral infection
US6218105B1 (en) * 1996-07-19 2001-04-17 Kathleen S. Hall High throughput papilloma virus in vitro infectivity assay
WO1999051776A1 (en) * 1998-04-07 1999-10-14 Southern Research Institute High-throughput method for screening for antiviral activity
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
HK1048138B (zh) * 1999-04-15 2009-06-12 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen

Also Published As

Publication number Publication date
CA2445911A1 (en) 2002-11-14
NZ529094A (en) 2005-07-29
CA2445911C (en) 2011-05-24
EP1388008A1 (de) 2004-02-11
US7163787B2 (en) 2007-01-16
EP1256803A1 (de) 2002-11-13
ATE410679T1 (de) 2008-10-15
AU2002306089B2 (en) 2007-06-28
EP1388008B1 (de) 2008-10-08
US20040086850A1 (en) 2004-05-06
WO2002090982A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DK0988378T4 (da) En fremgangsmåde til in vitro molekylær udvikling af proteinfunktion
DK1252328T3 (da) Fremgangsmåde og midler til isolering af mikroorganismer
DK1332209T3 (da) Samlinger af repeatproteiner indeholdende repeatmoduler
DE602004030472D1 (de) Vorrichtung und verfahren zur quantifizierung von mrna aus vollblut mit hohem durchsatz
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
PT1325343E (pt) Aumento do rendimento num analisador clinico automatico atraves da divisao de ensaios em funcao do tipo de ensaios
DK1680681T3 (da) Fremgangsmåde og apparat til vurdering af polypeptidaggregering
WO2003102578A3 (en) High throughput cellular response assay using microarrays
DK1388008T3 (da) Fremgangsmåder til identifikation af antivirale forbindelser
NO20006109L (no) Analytisk metode som benytter multippel virusmerking
ATE462001T1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
DE602005025401D1 (de) Hes verfahren unter verwendung davon
WO2004046314A3 (en) Methods for detecting asymmetric dimethylarginine in a biological sample
DE602006012072D1 (de) Tests der molekularen oder subzellulären interaktivität unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
Singh et al. Characterization of seed storage proteins from chickpea using 2D electrophoresis coupled with mass spectrometry
MXPA01006914A (es) Metodos para identificar combinaciones de entidades como terapeuticas.
ATE545460T1 (de) Proteomanalyseverfahren für phosphoryliertes protein
WO2007008647A3 (en) Diagnosing and grading gliomas using a proteomics approach
ATE469238T1 (de) Verwendung von fluor-nmr zum screening mit hohem durchsatz
WO2002066982A8 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
ATE412187T1 (de) Screening test
Burgess et al. Strategies to dissect parasite proteomes
Cuervo et al. Validation of an in vitro potency test for the Cuban Hepatitis B vaccine
ATE414905T1 (de) Diabetesmodell
DK1299559T3 (da) Fremgangsmåde til identificering af inhibitorer for det anafase-promoverende kompleks